Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.74)
# 2,077
Out of 5,015 analysts
75
Total ratings
43.86%
Success rate
7.64%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $22 → $20 | $20.01 | -0.05% | 17 | May 8, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $16.12 | -6.92% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $14.00 | -42.86% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $17.18 | +191.04% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $138.34 | -1.69% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $6.38 | +150.98% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $10.18 | +509.04% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $3.01 | +299.33% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $22.10 | +393.21% | 3 | Dec 12, 2023 | |
| ABOS Acumen Pharmaceuticals | Initiates: Buy | $8 | $2.13 | +275.59% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $5.37 | +86.22% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $8.55 | +1,069.59% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $11.59 | -48.23% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $3.91 | +437.08% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $164.99 | -86.06% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $32.65 | +10.26% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
May 8, 2025
Maintains: Hold
Price Target: $22 → $20
Current: $20.01
Upside: -0.05%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $16.12
Upside: -6.92%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $14.00
Upside: -42.86%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $17.18
Upside: +191.04%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $138.34
Upside: -1.69%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $6.38
Upside: +150.98%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $10.18
Upside: +509.04%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $3.01
Upside: +299.33%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $22.10
Upside: +393.21%
Acumen Pharmaceuticals
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $2.13
Upside: +275.59%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $5.37
Upside: +86.22%
Nov 11, 2022
Maintains: Buy
Price Target: $140 → $100
Current: $8.55
Upside: +1,069.59%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $11.59
Upside: -48.23%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $3.91
Upside: +437.08%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $164.99
Upside: -86.06%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $32.65
Upside: +10.26%